Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | C1R | P00736 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27864957 | 0.84 | CCNE2 (0.53) | TLR7 | |
| SCHEMBL1458846 | 0.82 | KDM1A (0.49) | PDE5AKDM1ATRPA1 | |
| SCHEMBL1458504 | 0.81 | LATS1 (0.53) | PDE5AHTTKDM1ANLRP3 | |
| SCHEMBL16666367 | 0.76 | USP1 (0.39) | PGK1C1RKDM1ATRPA1 | |
| SCHEMBL3911393 | 0.76 | LATS1 (0.49) | HTT | |
| SCHEMBL23040982 | 0.76 | C1R (0.41) | PDE2AC1RAPPHTTNLRP3 | |
| SCHEMBL29636633 | 0.76 | C1R (0.41) | PDE2AC1RAPPHTTNLRP3 | |
| SCHEMBL2531193 | 0.76 | C1R (0.43) | C1RAPPHTTTRPA1NLRP3 | |
| SCHEMBL29909108 | 0.76 | C1R (0.43) | C1RAPPHTTTRPA1NLRP3 | |
| SCHEMBL16666999 | 0.75 | DDR1 (0.42) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796180-B2 | Aminoquinazoline compounds for combating invertebrate pests | BASF SE (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-2480537-A1 | AMINOQUINAZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120178622-A1 | Aminoquinazoline Compounds for Combating Invertebrate Pests | BASF SE (DE) | 2012-07-12 | — | — | US | disclosed |
| CN-102574817-A | Aminoquinazoline compounds for combating invertebrate pests | BASF SE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036074-A1 | AMINOQUINAZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178622-A1 | Aminoquinazoline Compounds for Combating Invertebrate Pests | AAAS, ATL3, H1-3 | PDE2A 364/4885PGK1 2182/4885C1R 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.